Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

iMRI Guided Resection in Cerebral Glioma Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01479686
Recruitment Status : Active, not recruiting
First Posted : November 24, 2011
Last Update Posted : February 22, 2019
Sponsor:
Information provided by (Responsible Party):
Jinsong Wu, Huashan Hospital

Brief Summary:

Many clinical studies have been reported on iMRI, however, their evidence levels are relatively not as good as what people hope they will be. Based on the available literature, there is, at best, level 2 evidence that iMRI-guided surgery is more effective than conventional neuronavigation-guided surgery.

The investigators aim to do a single center prospective randomized triple-blind controlled clinical trial to assess the effect of 3.0T high-field intraoperative MRI-guided glioma resection on surgical efficiency and progression-free survival of malignant glioma to provide a level 2A evidence for its clinical application.


Condition or disease Intervention/treatment Phase
Glioma Procedure: iMRI Procedure: conventional neuronavigation Phase 3

Detailed Description:

Since the first introduction of the GE Signa System by the Brigham and Women's Hospital as the world's first intraoperative MRI in 1993, iMRI has been so increasingly applied that it has been one of the most important techniques and concepts in the field of neurosurgery. Many clinical studies have been reported on this respect, however, their evidence levels are relatively not as good as what people hope they will be.Based on the available literature, there is, at best, level 2B evidence that iMRI-guided surgery is more effective than conventional neuronavigation-guided surgery.

Rationale: Intraoperative magnetic resonance imaging (MRI)-guided intracranial surgery, one of whose most frequently reported indications is cerebral glioma surgery, may help update images for navigational systems, providing data on the extent of resection and localization of tumor remnants, and thereby enable intraoperative reliable immediate resection control to eliminate the effect of brain shift on the extent of resection. Intraoperative MRI systems can be divided into low-field intraoperative MRI(0.5T or less) and high-field intraoperative MRI (1.5T or more) according to their various field strengths. The latter enables intraoperative imaging at higher quality and more available imaging modalities but with more cost and equipment requirements.

Purpose: We aim to do a single center prospective randomized triple-blind controlled clinical trial to assess the effect of 3.0T high-field intraoperative MRI-guided glioma resection on surgical efficiency and progression-free survival of malignant glioma. We hypothesize that the use of high-field intraoperative MRI will enable more complete tumor resection than conventional neuronavigation-guided resection,reducing the morbidity and leading to more improved progression-free survival and quality of life in patients with malignant glioma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 321 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: 3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial
Study Start Date : September 2011
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: conventional neuronavigation
conventional neuronavigation guided resection in adults with glioma
Procedure: conventional neuronavigation
conventional neuronavigation guided resection in adults with glioma

Experimental: intraoperative MRI
iMRI guided resection in adults with glioma
Procedure: iMRI
3.0TiMRI guided resection in adults with glioma




Primary Outcome Measures :
  1. Extent of resection [ Time Frame: 3 years ]
    Extent of resection (EOR) based on early postoperative MRI obtained within 72 h after surgery. Gross total resection (GTR) was defined as the complete disappearance of all enhancing lesions (T1WI) for HGG and the complete disappearance of all nonenhancing (T2WI FLAIR) lesions for LGG. The EOR were quantitatively volumetric analyses for all gliomas and gliomas grouped according to eloquent areas and non-eloquent areas, and stratified as: GTR, 100% resection; subtotal resection ≥ 90% resection, partial resection ≥ 70% resection, biopsy, resection ≥98% for OS advantage (HGG) and resection ≥90% for OS advantage (LGG).


Secondary Outcome Measures :
  1. OS [ Time Frame: 10 years ]
    Overall survival analyses for all gliomas and gliomas grouped according to eloquent areas and non-eloquent areas.

  2. PFS [ Time Frame: 10 years ]
    Neuropathological confirmed non-glioma lesions or benign histologies are excluded from the secondary endpoints follow up. All participants were observed, with serial clinical evaluations and MRI scans every 3 months following interventions, which was the routine for these diseases. Progression was defined in accordance with RANO criteria.

  3. Postoperative complications [ Time Frame: after surgery ]
    Postoperative complications: e.g., postoperative epilepsy, infection, bleeding and infarction.

  4. Health economics [ Time Frame: after surgery ]
    Health economics: surgical time, surgical cost, postoperative hospitalization days, and hospitalization expenses

  5. MRI-related adverse events [ Time Frame: after surgery ]
    MRI-related adverse events: risks of airway management, burn, MRI mechanical damage, and other safety analysis.

  6. Surgery related morbidity [ Time Frame: 3 years ]
    Assessment of motor and language functions (Morbidity): whether there are newly postoperative hemiplegia or aphasia.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Individuals aged 18-70 years with highly suspected (as assessed by study surgeon), newly diagnosed, untreated malignant glioma (see appendix 1)
  2. Individuals with supratentorial gliomas with bodies involving in frontal lobe, temporal lobe, parietal lobe, occipital lobe or insular lobe
  3. Individuals with the preoperative assessment that radiological radicality should be achieved
  4. Individuals either with or without tumor in eloquent areas (see appendix 2)
  5. Karnofsky performance scale 70 or more
  6. All patients gave written informed consent.

Appendix 1. Histological types(WHO 2007):

  1. Astrocytic tumours:Pilomyxoid astrocytoma 9425/3 Pleomorphic xanthoastrocytoma 9424/3 Diffuse astrocytoma 9400/3 Fibrillary astrocytoma 9420/3 Gemistocytic astrocytoma 9411/3 Protoplasmic astrocytoma 9410/3 Anaplastic astrocytoma 9401/3 Glioblastoma 9440/3 Giant cell glioblastoma 9441/3 Gliosarcoma 9442/3
  2. Oligodendroglial tumours:Oligodendroglioma 9450/3 Anaplastic oligodendroglioma 9451/3
  3. Oligoastrocytic tumours:Oligoastrocytoma 9382/3 Anaplastic oligoastrocytoma 9382/3
  4. Ependymal tumours:Ependymoma 9391/3 Cellular 9391/3 Papillary 9393/3 Clear cell 9391/3 Tanycytic 9391/3 Anaplastic ependymoma 9392/3

Morphology code of the International Classification of Diseases for Oncology (ICD-O) {614A} and the Systematized Nomenclature of Medicine (http://snomen.org). Behaviour is coded /0 for benign tumours, /3 for malignant tumours and /1 for borderline or uncertain behaviour.

Tumor grade: grade II~IV according to the latest WHO grading criteria;

Appendix 2. Tumor location in eloquent areas:

located in or close to areas of the dominant-hemisphere that associated with motor or language functions, including:

  1. Frontal lobe, which divided into inferior frontal gyrus (BA44-Pars opercularis, BA45-Pars triangularis/Broca's area), middle frontal gyrus (BA9, BA46), superior frontal gyrus (BA4, BA6, BA8), primary motor cortex (BA4), premotor cortex (BA6), and supplementary motor area (BA6)
  2. Parietal lobe, which divided into inferior parietal lobule (BA40-supramarginal gyrus, BA39-angular gyrus), parietal operculum (BA43), and primary somatosensory cortex (BA1, BA2, BA3)
  3. Temporal lobe, which divided into transverse temporal gyrus (BA41, BA42), superior temporal gyrus (BA38, BA22/Wernicke's area), middle temporal gyrus (BA21)
  4. Insular lobe.

Exclusion Criteria:

  1. Individuals with age < 18 years or > 70 years
  2. Tumours of the midline, basal ganglia, cerebellum, or brain stem
  3. Recurrent gliomas after surgery (except needle biopsy)
  4. Primary gliomas with history of radiotherapy or chemotherapy
  5. Contraindications precluding intraoperative MRI-guided surgery
  6. Inability to give informed consent
  7. KPS < 70
  8. Renal insufficiency or hepatic insufficiency
  9. History of malignant tumours at any body site
  10. Tumour locations (in important eloquent area) do not enable complete resection of tumour.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01479686


Locations
Layout table for location information
China, Shanghai
Department of Neurologic Surgery, Huashan Hospital, Shanghai Medical College, Fudan University
Shanghai, Shanghai, China, 200040
Sponsors and Collaborators
Huashan Hospital
Investigators
Layout table for investigator information
Study Chair: Liang-fu Zhou, M.D. Huashan Hospital
Principal Investigator: Ying Mao, M.D., Ph.D Huashan Hospital
Principal Investigator: Jin-song Wu, M.D., Ph.D Huashan Hospital
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jinsong Wu, M.D.,Ph.D., Huashan Hospital
ClinicalTrials.gov Identifier: NCT01479686    
Other Study ID Numbers: XBR2011022
First Posted: November 24, 2011    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019
Keywords provided by Jinsong Wu, Huashan Hospital:
GLIOMA
NEURONAVIGATION
INTERVENTIONAL MRI
Additional relevant MeSH terms:
Layout table for MeSH terms
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue